Bigbear Pharmaceutical·Medication Guide

• Adverse Reactions and Precautions of Lenalidomide

  Lenalidomide is an oral immunomodulator developed by Celgene Corporation, primarily used to treat hematologic malignancies such as multiple myeloma, m···【Read More】

  Update: 2026-05-19Source: Haiou HealthViews: 93

• Purchasing Channels for Pomalidomide

  Pomalidomide is a small-molecule immunomodulatory drug that exerts its therapeutic effects by inhibiting tumor cell proliferation, inducing tumor cell···【Read More】

  Update: 2026-05-15Source: Haiou HealthViews: 115

• The price of pomalidomide

  Pomalidomide is an oral immunomodulatory prescription drug, commonly available in capsule form. It works by regulating the immune system to inhibit tu···【Read More】

  Update: 2026-05-15Source: Haiou HealthViews: 102

• Purchase Channels for Bedaquiline

  Bedaquiline is a diarylquinoline antimycobacterial drug specifically used to treat a particular type of pulmonary tuberculosis. As a prescription drug···【Read More】

  Update: 2026-05-13Source: Haiou HealthViews: 107

• Price of Bedaquiline

  Bedaquiline is a diarylquinoline antibacterial prescription drug, commonly available in tablet form. It works by inhibiting the ATP synthase in Mycoba···【Read More】

  Update: 2026-05-13Source: Haiou HealthViews: 119

• Ways to Purchase Encorafenib

  Encorafenib is a targeted therapy drug designed for cancer patients harboring BRAF V600E or V600K mutations. It is frequently used in combination with···【Read More】

  Update: 2026-05-12Source: Haiou HealthViews: 114

• Price of Encorafenib

  Encorafenib is a targeted therapy drug designed for cancer patients harboring BRAF V600E or V600K mutations. It is typically used in combination with ···【Read More】

  Update: 2026-05-12Source: Haiou HealthViews: 112

• FDA Approves Binimetinib in Combination with Encorafenib for Unresectable or Metastatic Melanoma with BRAF Mutations

  On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination regimen of Binimetinib and Encorafenib for the treatment of pat···【Read More】

  Update: 2026-05-12Source: Haiou HealthViews: 116

• FDA Approves Binimetinib in Combination with Encorafenib for the Treatment of Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation

  October 12, 2023 – New York – (Business Wire)Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi®···【Read More】

  Update: 2026-05-12Source: Haiou HealthViews: 119

• What Does Binimetinib Treat? Indications and Therapeutic Effects of Binimetinib

  Binimetinib is indicated for use in combination with encorafenib for the treatment of advanced melanoma and non-small cell lung cancer (NSCLC) harbori···【Read More】

  Update: 2026-05-12Source: Haiou HealthViews: 113

• FDA Approves Cabozantinib for Previously Treated Patients with Advanced Neuroendocrine Tumors

  March 26, 2025--Alameda, CA--(BUSINESS WIRE)Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approve···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 120

• FDA Approves Cabozantinib for Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

  September 17, 2021--Alameda, CA--(BUSINESS WIRE)Exelixis, Inc. (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration (FDA) has approved ···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 106

• FDA Approves Nivolumab in Combination with Cabozantinib as First-Line Treatment for Advanced Renal Cell Carcinoma

  January 22, 2021--Princeton, NJ--(BUSINESS WIRE)Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approv···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 123

• ​FDA Approves Cabozantinib Tablets for the Treatment of Previously Treated Hepatocellular Carcinoma

  January 14, 2019--Alameda, CA--(BUSINESS WIRE)Exelixis, Inc. (Nasdaq: EXEL) announced that the U.S. Food and Drug Administration (FDA) has approved ca···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 108

• FDA Approves Cabozantinib Tablets for Previously Untreated Advanced Renal Cell Carcinoma

  December 19, 2017 — South San Francisco, CA — (Business Wire)Exelixis, Inc. (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration (FDA) ···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 107